Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- MZOR +6.6%, (sees Q3 revs above expectations)
M&A news:
- CLNT +31% (announced that its wholly-owned subsidiary, Sharing Economy Investment Limited, has entered into an exclusivity agreement with Inspirit Studio, regarding a potential acquisition by SEI of not less than 51% of Inspirit Studio)
Other news:
- TROV +14.1% (confirms FDA grants orphan drug designation to Trovagene's PLK1 Inhibitor, PCM-075)
- INSG +12% (announce a new global strategic partnership)
- CGEN +9.9% (discloses new data demonstrating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy)
- FLXN +6.8% (will hold conf call today to update FDA approval of ZILRETTA)
- ITEK +5% (Opaleye Management disclosed 5.76% passive stake)
- SSL +3.1% (no longer pursue the preferred funding option, as described in the First Announcement, of issuing up to 43 million ordinary shares through an accelerated book-build process)
- CDXC +3% (appoints Kevin Farr as new CFO)
- ERIC +2.1% (proposes Ronnie Leten as new Chairman)
- AKS +1.3% (will implement electrode surcharge for all stainless product shipments effective October 29), .
Analyst comments:
- MULE +5.1% (upgraded to Buy from Neutral at Goldman)
- JUNO +1.8% ( target raised to $56 at Maxim Group )
- KSS +1.6% (upgraded to Outperform from Market Perform at Telsey Advisory Group)
- BTI +1.4% (upgraded to Buy from Neutral at Goldman)
- BLUE +1.4% ( target raised to $170 from $100 at Maxim Groupt )
- JNJ +1% (upgraded to Outperform from Market Perform at Wells Fargo)
- MS +0.8% (upgraded to Outperform from Neutral at Credit Suisse)
- ETFC +0.7% (upgraded to Buy from Neutral at BofA/Merrill)
- CTRP +0.5% (initiated with a Overweight at Barclays)
- DIS +0.5% (upgraded to Top Pick at RBC Capital Mkts)
Gapping down